Type I interferon (IFN) score may effectively predict disease progression in limited cutaneous systemic sclerosis (lcSSc), with patients having a high IFN activity presenting worse clinical outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback